RecruitingNCT06766175

Impact of Chronic Cough on Activities of Daily Living and Response to Acute High-intensity Exercise

Sponsor

University of Leeds

Enrollment

129 participants

Start Date

Dec 1, 2024

Study Type

OBSERVATIONAL

Conditions

Chronic Cough (CC)

Summary

Chronic cough is a common and debilitating condition that affects up to 10% of the global population. The health impact of chronic cough is multifaceted and manifests both physical and psychological symptoms including syncope, chest pain, lethargy, depression and anxiety. It is now also recognised that chronic cough often leads to social isolation and may impact an individual's ability or confidence to undertake routine daily tasks / lead an active lifestyle. The primary aim of this study is therefore to characterise the impact of unexplained chronic cough on the ability to undertake daily activities - i.e., determine whether individuals with chronic cough exhibit impaired levels of physical activity during usual daily living when compared with healthy age, gender and BMI matched controls. A secondary aim is to assess the short-term impact of high-intensity exercise on cough (i.e., determine whether an acute bout of exercise alters cough frequency and/or severity).

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Age >18 years
Chronic cough as per European Respiratory Society definition (>8 weeks duration)
High symptom burden (i.e., cough visual analogue scale >40 mm at pre-study screening)
Chest radiograph or CT within 3 years of the screening visit with no abnormalities considered to contribute to chronic cough

Exclusion Criteria11

Smokers or individuals who gave up smoking within 12 months
Smoking history >20 pack-years
Long-COVID or post-COVID syndrome (defined as symptoms lasting over 12-weeks in duration)
Recent exacerbation of cough within 4 weeks of inclusion
Respiratory tract infection within 4 weeks of inclusion
Currently taking any of the following medications:
ACE inhibitors and within 3 months of inclusion
Antitussives (opioids, pregabalin, gabapentin, amitriptyline, nortriptyline, or over the-counter medications) within 2 weeks of inclusion
Medical treatments for gastro-oesophageal reflux disease (GORD), eosinophilic bronchitis or other cough related conditions, initiated or changed (i.e., not in a stable regimen) for 4 weeks prior to inclusion
Medical history of asthma or exercise-induced bronchoconstriction (EIB), COPD, or chronic bronchitis in the judgement of the investigator
Medical conditions/history or other circumstances which, in the judgement of the investigators, could increase the risk of adverse events or bias the study results